Separate terms with OR to return results that match either term.
 
Clear All
9,752 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
43598-0255-52 43598-0255 Zoledronic acid Zoledronic acid 4.0 mg/100mL Ancillary Therapy Bisphosphonate Intravenous Jan. 15, 2019 In Use
68001-0437-25 68001-0437 Zoledronic acid Zoledronic acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous June 29, 2020 In Use
50742-0416-05 50742-0416 zoledronic acid Zoledronic acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Feb. 19, 2020 In Use
67457-0920-05 67457-0920 Zoledronic acid Zoledronic acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Oct. 12, 2020 In Use
00006-0568-40 00006-0568 Vorinostat Zolinza 100.0 mg/1 Chemotherapy Enzyme Inhibitor HDAC Oral Oct. 6, 2006 In Use
00078-0387-25 00078-0387 Zoledronic Acid Zometa 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Aug. 20, 2001 Nov. 30, 2020 No Longer Used
00078-0590-61 00078-0590 Zoledronic Acid Zometa 4.0 mg/100mL Ancillary Therapy Bisphosphonate Intravenous Aug. 20, 2001 Jan. 31, 2020 No Longer Used
57881-0444-01 57881-0444 Ondansetron Zuplenz 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
57881-0444-10 57881-0444 Ondansetron Zuplenz 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
57881-0448-01 57881-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
57881-0448-10 57881-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct. 8, 2014 In Use
43288-0104-01 43288-0104 Ondansetron Zuplenz Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 5, 2010 Nov. 16, 2013 No Longer Used
43288-0104-10 43288-0104 Ondansetron Zuplenz Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 5, 2010 Nov. 30, 2015 No Longer Used
43288-0108-01 43288-0108 Ondansetron Zuplenz Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 5, 2010 Nov. 16, 2013 No Longer Used
43288-0108-10 43288-0108 Ondansetron Zuplenz Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 5, 2010 Nov. 30, 2015 No Longer Used
49884-0324-11 49884-0324 Ondansetron Zuplenz Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 5, 2010 Sept. 15, 2011 No Longer Used
49884-0324-52 49884-0324 Ondansetron Zuplenz Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 5, 2010 Sept. 15, 2011 No Longer Used
49884-0324-62 49884-0324 Ondansetron Zuplenz Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 5, 2010 Nov. 30, 2012 No Longer Used
49884-0325-11 49884-0325 Ondansetron Zuplenz Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 5, 2010 Nov. 11, 2011 No Longer Used
49884-0325-52 49884-0325 Ondansetron Zuplenz Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 5, 2010 Nov. 11, 2011 No Longer Used
49884-0325-62 49884-0325 Ondansetron Zuplenz Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 5, 2010 July 31, 2012 No Longer Used
89141-0444-01 89141-0444 Ondansetron Zuplenz 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 2, 2010 In Use
89141-0444-30 89141-0444 Ondansetron Zuplenz 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 31, 2016 Feb. 23, 2023 In Use
89141-0448-01 89141-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 2, 2010 Feb. 23, 2021 In Use
89141-0448-30 89141-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 31, 2016 Feb. 23, 2021 In Use
61958-1701-01 61958-1701 Idelalisib Zydelig 100.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral July 23, 2014 In Use
61958-1702-01 61958-1702 Idelalisib Zydelig 150.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral July 23, 2014 In Use
00078-0640-70 00078-0640 Ceritinib Zykadia 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral April 29, 2014 Feb. 29, 2020 In Use
57894-0195-06 57894-0195 Abiraterone Acetate Zytiga 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 17, 2017 In Use
57894-0195-15 57894-0195 Abiraterone Acetate Zytiga 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 17, 2017 In Use
57894-0184-12 57894-0184 Abiraterone Acetate Zytiga 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 17, 2017 April 18, 2017 No Longer Used
57894-0150-12 57894-0150 Abiraterone Acetate Zytiga 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 28, 2011 In Use
57894-0150-25 57894-0150 Abiraterone Acetate Zytiga 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Sept. 1, 2015 Aug. 31, 2018 In Use
55111-0496-05 55111-0496 capecitabine capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 10, 2020 In Use
55111-0496-60 55111-0496 capecitabine capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 10, 2020 In Use
55111-0497-04 55111-0497 capecitabine capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 10, 2020 In Use
55111-0497-05 55111-0497 capecitabine capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 10, 2020 In Use
70121-1482-02 70121-1482 carmustine carmustine Chemotherapy Alkylating Agent Nitrosourea Intravenous Oct. 22, 2018 In Use
39822-2100-02 39822-2100 dactinomycin dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous July 31, 2019 In Use
68180-0738-01 68180-0738 decitabine decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 6, 2019 In Use
25021-0207-05 25021-0207 Doxorubicin Hydrochloride doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 31, 2013 Sept. 30, 2020 No Longer Used
25021-0207-25 25021-0207 Doxorubicin Hydrochloride doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 31, 2013 Aug. 31, 2020 No Longer Used
25021-0207-51 25021-0207 Doxorubicin Hydrochloride doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct. 31, 2013 Sept. 30, 2020 No Longer Used
00378-3097-85 00378-3097 everolimus everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
68001-0517-36 68001-0517 fosaprepitant fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Aug. 23, 2021 In Use
25021-0462-74 25021-0462 fulvestrant fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Aug. 1, 2019 In Use
25021-0234-10 25021-0234 Gemcitabine Hydrochloride gemcitabine 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 29, 2014 In Use
55111-0686-07 55111-0686 Gemcitabine gemcitabine 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
55111-0687-25 55111-0687 Gemcitabine gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 25, 2011 In Use
68001-0490-05 68001-0490 imatinib mesylate imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral March 26, 2021 In Use

Found 9,752 results in 18 milliseconds — Export these results